What is the contribution of IgE to nasal polyposis?

[1]  V. Backer,et al.  EUFOREA Expert Board Meeting on Uncontrolled Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and Biologics: Definitions and Management. , 2020, The Journal of allergy and clinical immunology.

[2]  S. Galli,et al.  Omalizumab in "non-IgE mediated" diseases. , 2020, The Journal of allergy and clinical immunology.

[3]  C. Bachert,et al.  D202 CONTINUED SAFETY/EFFICACY OF OMALIZUMAB IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS: AN OPEN-LABEL EXTENSION STUDY , 2020 .

[4]  C. Bachert,et al.  Add-on mepolizumab for chronic rhinosinusitis with nasal polyps: SYNAPSE study , 2020, Pneumologie.

[5]  P. Tassinari,et al.  Omalizumab restores the ability of human plasmacytoid dendritic cells to induce Foxp3+Tregs , 2020, European Respiratory Journal.

[6]  W. Busse.  Does IgE Have a Role in Aspirin-exacerbated Respiratory Disease? , 2020, American Journal of Respiratory and Critical Care Medicine.

[7]  C. Bachert,et al.  Efficacy and safety of omalizumab in nasal polyposis: two randomized phase III trials. , 2020, The Journal of allergy and clinical immunology.

[8]  Kecheng Zhang,et al.  IgM and IgA in addition to IgG autoantibodies against FcɛRIα are frequent and associated with disease markers of chronic spontaneous urticaria , 2020, Allergy.

[9]  K. Okubo,et al.  Add-on omalizumab for inadequately controlled severe pollinosis despite standard-of-care: a randomized study. , 2020, The journal of allergy and clinical immunology. In practice.

[10]  K. Schäkel,et al.  Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020 , 2020, International Archives of Allergy and Immunology.

[11]  Y. Hasegawa,et al.  Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial , 2020, American journal of respiratory and critical care medicine.

[12]  R. Schleimer,et al.  Formation of nasal polyps: The roles of innate type 2 inflammation and deposition of fibrin. , 2020, The Journal of allergy and clinical immunology.

[13]  C. Bachert,et al.  Biologics for chronic rhinosinusitis with nasal polyps. , 2020, The Journal of allergy and clinical immunology.

[14]  K. Bergmann,et al.  Omalizumab in patients with NSAIDs-exacerbated respiratory disease. , 2020, Rhinology.

[15]  W. Fokkens.  EPOS2020: a major step forward. , 2020, Rhinology.

[16]  C. Bachert,et al.  Staphylococcus aureus and its IgE-inducing enterotoxins in asthma: current knowledge , 2020, European Respiratory Journal.

[17]  T. Jardetzky,et al.  The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab , 2020, Nature Communications.

[18]  W. Busse,et al.  Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[19]  C. Bachert,et al.  Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials , 2019, The Lancet.

[20]  P. Tassinari,et al.  Late Breaking Abstract - IgE-FceR1 cross-linking impairs the capacity of plasmacytoid dendritic cells to induce in vitro functional regulatory T cells which can be restored by Omalizumab , 2019, Allergy and immunology.

[21]  C. Bachert,et al.  Chronic Rhinosinusitis with Nasal Polyps in Older Adults: Clinical Presentation, Pathophysiology, and Comorbidity , 2019, Current Allergy and Asthma Reports.

[22]  W. Flynn,et al.  Identification of a T follicular helper cell subset that drives anaphylactic IgE , 2019, Science.

[23]  C. Bachert,et al.  Staphylococcus aureus Orchestrates Type 2 Airway Diseases. , 2019, Trends in molecular medicine.

[24]  J. Bousquet,et al.  Sensitisation to staphylococcal enterotoxins and asthma severity: a longitudinal study in the EGEA cohort , 2019, European Respiratory Journal.

[25]  C. Hopkins.  Chronic Rhinosinusitis with Nasal Polyps. , 2019, The New England journal of medicine.

[26]  N. Higashi,et al.  Aspirin-exacerbated respiratory disease (AERD): Current understanding of AERD. , 2019, Allergology international : official journal of the Japanese Society of Allergology.

[27]  C. Bachert,et al.  Twelve-year follow-up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis , 2019, Clinical and Translational Allergy.

[28]  C. Bachert,et al.  Broad IgG repertoire in patients with chronic rhinosinusitis with nasal polyps regulates proinflammatory IgE responses. , 2019, The Journal of allergy and clinical immunology.

[29]  C. Bachert,et al.  Endoscopic Sinus Surgery for Type‐2 CRS wNP: An Endotype‐Based Retrospective Study , 2019, The Laryngoscope.

[30]  H. Hammad,et al.  Protein crystallization promotes type 2 immunity and is reversible by antibody treatment , 2019, Science.

[31]  B. Cho,et al.  Association of Chronic Rhinosinusitis With Depression and Anxiety in a Nationwide Insurance Population , 2019, JAMA otolaryngology-- head & neck surgery.

[32]  C. Bachert,et al.  Elevated IgE M1 prime transcripts in nasal tissues in patients with nasal polyps and asthma. , 2019, The Journal of allergy and clinical immunology.

[33]  O. Schmetzer,et al.  On the Lipophilic Nature of Autoreactive IgE in Chronic Spontaneous Urticaria , 2019, Theranostics.

[34]  Michael T. Beste,et al.  Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: A randomized, double‐blind, placebo‐controlled study , 2018, Allergy.

[35]  Yang Shen,et al.  Prevalence of allergic rhinitis comorbidity with asthma and asthma with allergic rhinitis in China: A meta-analysis. , 2019, Asian Pacific journal of allergy and immunology.

[36]  C. Davis,et al.  IgE-Mediated Food Allergy , 2018, Clinical Reviews in Allergy & Immunology.

[37]  M. Maurer,et al.  Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab , 2018, Allergy.

[38]  M. Kohanski,et al.  Biomarkers in Chronic Rhinosinusitis with Nasal Polyps. , 2018, Immunology and allergy clinics of North America.

[39]  A. Arrobas,et al.  Omalizumab for Severe Asthma: Beyond Allergic Asthma , 2018, BioMed research international.

[40]  S. Ferrucci,et al.  Elevated IgE to tissue factor and thyroglobulin are abated by omalizumab in chronic spontaneous urticaria , 2018, Allergy.

[41]  B. Lambrecht,et al.  FcεRI expression and IgE binding by dendritic cells and basophils in allergic rhinitis and upon allergen immunotherapy , 2018, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[42]  S. Hazen,et al.  Omalizumab can inhibit respiratory reaction during aspirin desensitization. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[43]  C. Bachert,et al.  In chronic spontaneous urticaria, IgE against staphylococcal enterotoxins is common and functional , 2018, Allergy.

[44]  C. Hopkins,et al.  Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study , 2018, Respiratory Research.

[45]  D. Ledford,et al.  Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history , 2018, Journal of asthma and allergy.

[46]  M. Maurer,et al.  The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change , 2018, Allergy. European Journal of Allergy and Clinical Immunology.

[47]  M. Maurer,et al.  The role and relevance of mast cells in urticaria , 2018, Immunological reviews.

[48]  C. Bachert,et al.  Atopic Comorbidities and Biomarkers of Type 2 Inflammation in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) Who Failed Intranasal Corticosteroids , 2018 .

[49]  N. Bhattacharyya,et al.  Nasal polyp IgE and IgG4 levels are elevated in aspirin-exacerbated respiratory disease , 2018 .

[50]  O. Schmetzer,et al.  IL‐24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria , 2017, The Journal of allergy and clinical immunology.

[51]  C. Bachert,et al.  Staphylococcus aureus controls interleukin-5 release in upper airway inflammation. , 2017, Journal of proteomics.

[52]  N. Papadopoulos,et al.  Plasmacytoid dendritic cells drive acute asthma exacerbations , 2017, The Journal of allergy and clinical immunology.

[53]  C. Bachert,et al.  Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial , 2017, The Journal of allergy and clinical immunology.

[54]  C. Hopkins,et al.  The effect of endoscopic sinus surgery on quality of life and absenteeism in patients with chronic rhinosinuitis - a multi-centre study. , 2017, Rhinology.

[55]  W. Busse,et al.  A randomized multicenter study evaluating Xolair persistence of response after long‐term therapy , 2017, The Journal of allergy and clinical immunology.

[56]  O. Schmetzer,et al.  Autoimmune chronic spontaneous urticaria: What we know and what we do not know , 2017, The Journal of allergy and clinical immunology.

[57]  C. Bachert,et al.  Extracellular eosinophilic traps in association with Staphylococcus aureus at the site of epithelial barrier defects in patients with severe airway inflammation , 2017, The Journal of allergy and clinical immunology.

[58]  S. Sánchez-Ramón,et al.  dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies , 2017, International journal of molecular sciences.

[59]  A. Giménez-Arnau,et al.  Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria , 2017, Allergy.

[60]  R. Hillenbrand,et al.  Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin , 2017, Theranostics.

[61]  Janko Brand,et al.  Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. , 2017, The Journal of allergy and clinical immunology.

[62]  J. Boyce,et al.  Aspirin-exacerbated respiratory disease: Mediators and mechanisms of a clinical disease. , 2017, The Journal of allergy and clinical immunology.

[63]  L. Rudmik,et al.  Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis , 2017, The Laryngoscope.

[64]  C. Bachert,et al.  Characterization of human and Staphylococcus aureus proteins in respiratory mucosa by in vivo- and immunoproteomics. , 2017, Journal of proteomics.

[65]  R. Schleimer.  Immunopathogenesis of Chronic Rhinosinusitis and Nasal Polyposis. , 2017, Annual review of pathology.

[66]  P. O'Byrne,et al.  Anti-IgE and Biologic Approaches for the Treatment of Asthma. , 2017, Handbook of experimental pharmacology.

[67]  C. Cingi,et al.  Aspirin-exacerbated respiratory disease and current treatment modalities , 2017, European Archives of Oto-Rhino-Laryngology.

[68]  A. Minni,et al.  Effects of omalizumab therapy on allergic rhinitis: a pilot study. , 2016, European review for medical and pharmacological sciences.

[69]  C. Bachert,et al.  Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: A multicenter study in Europe, Asia, and Oceania. , 2016, The Journal of allergy and clinical immunology.

[70]  S. Durham,et al.  Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma , 2016, European Respiratory Journal.

[71]  C. Bachert,et al.  The quest for autoreactive antibodies in nasal polyps. , 2016, The Journal of allergy and clinical immunology.

[72]  R. Chaudhuri,et al.  Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study) , 2016, BMJ Open.

[73]  R. Schleimer,et al.  Chronic Rhinosinusitis with Nasal Polyps. , 2016, The journal of allergy and clinical immunology. In practice.

[74]  Y. Hasegawa,et al.  Omalizumab reduces cysteinyl leukotriene and 9α,11β-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease. , 2016, The Journal of allergy and clinical immunology.

[75]  C. Bachert,et al.  Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. , 2016, The Journal of allergy and clinical immunology.

[76]  C. Bachert,et al.  The response to nasal allergen provocation with grass pollen is reduced in patients with chronic rhinosinusitis with nasal polyposis and grass sensitization , 2016, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[77]  J. Mullol,et al.  Nasal polyps in patients with asthma: prevalence, impact, and management challenges , 2016, Journal of asthma and allergy.

[78]  W. Fokkens,et al.  International Consensus Statement on Allergy and Rhinology: Rhinosinusitis , 2016, International forum of allergy & rhinology.

[79]  C. Bachert,et al.  Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis. , 2015, The Journal of allergy and clinical immunology.

[80]  A. Peters,et al.  Cytokines in Chronic Rhinosinusitis. Role in Eosinophilia and Aspirin-exacerbated Respiratory Disease. , 2015, American journal of respiratory and critical care medicine.

[81]  C. Akdis,et al.  T-cell regulation during viral and nonviral asthma exacerbations. , 2015, The Journal of allergy and clinical immunology.

[82]  O. Laccourreye,et al.  Efficacy of tobramycin aerosol in nasal polyposis. , 2015, European annals of otorhinolaryngology, head and neck diseases.

[83]  C. Bachert,et al.  Local Immunoglobulin E in the Nasal Mucosa: Clinical Implications , 2015, Allergy, asthma & immunology research.

[84]  Tae Wook Kang,et al.  Altered Quality of Life and Psychological Health (SCL-90-R) in Patients With Chronic Rhinosinusitis With Nasal Polyps , 2015, The Annals of otology, rhinology, and laryngology.

[85]  D. Conrad,et al.  Inhibition of CD23-mediated IgE transcytosis suppresses the initiation and development of allergic airway inflammation , 2015, Mucosal Immunology.

[86]  J. Wee,et al.  Prevalence of Nasal Polyps and its Risk Factors: Korean National Health and Nutrition Examination Survey 2009-2011 , 2015, American journal of rhinology & allergy.

[87]  R. Srikantha,et al.  Human Eosinophils Express the High Affinity IgE Receptor, FcεRI, in Bullous Pemphigoid , 2014, PloS one.

[88]  S. Holgate.  New strategies with anti-IgE in allergic diseases , 2014, The World Allergy Organization journal.

[89]  T. Laidlaw,et al.  Elevated Total Serum IgE in Nonatopic Patients with Aspirin-exacerbated Respiratory Disease , 2014, American journal of rhinology & allergy.

[90]  M. Citardi,et al.  Analysis of comorbidities and objective parameters in refractory chronic rhinosinusitis , 2013, The Laryngoscope.

[91]  Mi-Ae Kim,et al.  Clinical Significance of Immunoglobulin E Responses to Staphylococcal Superantigens in Patients with Aspirin-Exacerbated Respiratory Disease , 2013, International Archives of Allergy and Immunology.

[92]  L. Rosenwasser,et al.  Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells , 2013, Clinical and Translational Allergy.

[93]  C. Bachert,et al.  Inflammatory Patterns in Upper Airway Disease in the Same Geographical Area may Change over Time , 2013, American journal of rhinology & allergy.

[94]  Y. Okayama,et al.  Significantly High Levels of Anti-dsDNA Immunoglobulin E in Sera and the Ability of dsDNA to Induce the Degranulation of Basophils from Chronic Urticaria Patients , 2013, International Archives of Allergy and Immunology.

[95]  A. Peters,et al.  Incidence and associated premorbid diagnoses of patients with chronic rhinosinusitis. , 2013, Journal of Allergy and Clinical Immunology.

[96]  T. Casale,et al.  Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. , 2013, The New England journal of medicine.

[97]  C. Bachert,et al.  Local receptor revision and class switching to IgE in chronic rhinosinusitis with nasal polyps , 2013, Allergy.

[98]  M. Humbert,et al.  A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. , 2013, Chest.

[99]  C. Bachert,et al.  Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. , 2012, The Journal of allergy and clinical immunology.

[100]  A. Peters,et al.  Chapter 16: Determining the role of allergy in sinonasal disease. , 2013, American journal of rhinology & allergy.

[101]  N. Zhang,et al.  Chronic rhinosinusitis and asthma: novel understanding of the role of IgE ‘above atopy’ , 2012, Journal of internal medicine.

[102]  K. Van Steen,et al.  Specific IgE against Staphylococcus aureus enterotoxins: an independent risk factor for asthma. , 2012, The Journal of allergy and clinical immunology.

[103]  C. Corrigan,et al.  Airway Epithelium in Atopic and Nonatopic Asthma: Similarities and Differences , 2011, ISRN allergy.

[104]  C. Bachert,et al.  Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. , 2011, The Journal of allergy and clinical immunology.

[105]  C. Bachert,et al.  Activation-Induced Cytidine Deaminase (AID)-Associated Multigene Signature to Assess Impact of AID in Etiology of Diseases with Inflammatory Component , 2011, PloS one.

[106]  Overview on the pathomechanisms of allergic rhinitis , 2011, Asia Pacific allergy.

[107]  W. Calhoun,et al.  Can anti‐IgE therapy prevent airway remodeling in allergic asthma? , 2011, Allergy.

[108]  K. Schäkel,et al.  Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. , 2011, The Journal of allergy and clinical immunology.

[109]  P. Martus,et al.  IgE Mediated Autoallergy against Thyroid Peroxidase – A Novel Pathomechanism of Chronic Spontaneous Urticaria? , 2011, PloS one.

[110]  C. Bachert,et al.  Mucosal tissue polyclonal IgE is functional in response to allergen and SEB , 2011, Allergy.

[111]  K. Van Steen,et al.  Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthma. , 2010, The Journal of allergy and clinical immunology.

[112]  W. Busse,et al.  Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. , 2010, Respiratory medicine.

[113]  C. Bachert,et al.  Detection of Staphylococcus Aureus in Nasal Tissue with Peptide Nucleic Acid–Fluorescence in Situ Hybridization , 2009, American journal of rhinology & allergy.

[114]  C. Bachert,et al.  Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease. , 2008, The Journal of allergy and clinical immunology.

[115]  J. Plutzky,et al.  Leukotriene E4 Activates Peroxisome Proliferator-activated Receptor γ and Induces Prostaglandin D2 Generation by Human Mast Cells* , 2008, Journal of Biological Chemistry.

[116]  B. Sutton,et al.  IgE in allergy and asthma today , 2008, Nature Reviews Immunology.

[117]  C. Bachert,et al.  Role of staphylococcal superantigens in upper airway disease , 2008, Current opinion in allergy and clinical immunology.

[118]  J. Kinet,et al.  New developments in FcεRI regulation, function and inhibition , 2007, Nature Reviews Immunology.

[119]  C. Bachert,et al.  Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. , 2006, The Journal of allergy and clinical immunology.

[120]  H. Karasuyama,et al.  Different Stabilities of the Structurally Related Receptors for IgE and IgG on the Cell Surface Are Determined by Length of the Stalk Region in Their α-Chains1 , 2006, The Journal of Immunology.

[121]  J. Bousquet,et al.  The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. , 2005, The Journal of allergy and clinical immunology.

[122]  J. Klossek,et al.  Prevalence of nasal polyposis in France: a cross‐sectional, case–control study , 2005, Allergy.

[123]  P. Belliveau.  Omalizumab: a monoclonal anti-IgE antibody. , 2005, MedGenMed : Medscape general medicine.

[124]  C. Bachert,et al.  Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis. , 2004, The Journal of allergy and clinical immunology.

[125]  D. Conley,et al.  Immunoglobulin E to Staphylococcal and Streptococcal Toxins in Patients with Chronic Sinusitis/Nasal Polyposis , 2004, The Laryngoscope.

[126]  Stephen T Holgate,et al.  Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. , 2004, American journal of respiratory and critical care medicine.

[127]  C. Bachert,et al.  Aspirin Sensitivity and IgE Antibodies to Staphylococcus aureus Enterotoxins in Nasal Polyposis: Studies on the Relationship , 2004, International Archives of Allergy and Immunology.

[128]  Anne E. Shelburne,et al.  CD23 Trimers Are Preassociated on the Cell Surface Even in the Absence of Its Ligand, IgE1 , 2004, The Journal of Immunology.

[129]  T. Casale,et al.  Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[130]  L. Johansson,et al.  Prevalence of Nasal Polyps in Adults: The Skovde Population-Based Study , 2003, The Annals of otology, rhinology, and laryngology.

[131]  O. Noga,et al.  Immunological and Clinical Changes in Allergic Asthmatics following Treatment with Omalizumab , 2003, International Archives of Allergy and Immunology.

[132]  Claus Bachert,et al.  IgE to Staphylococcus aureus enterotoxins in serum is related to severity of asthma. , 2003, The Journal of allergy and clinical immunology.

[133]  K. Austen,et al.  Cysteinyl Leukotrienes and Uridine Diphosphate Induce Cytokine Generation by Human Mast Cells Through an Interleukin 4–regulated Pathway that Is Inhibited by Leukotriene Receptor Antagonists , 2002, The Journal of experimental medicine.

[134]  T. Casale,et al.  Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. , 2001, JAMA.

[135]  W. Busse,et al.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. , 2001, The Journal of allergy and clinical immunology.

[136]  C. Bachert,et al.  Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. , 2001, The Journal of allergy and clinical immunology.

[137]  T. Haahtela,et al.  Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. , 2000, The Journal of allergy and clinical immunology.

[138]  J. Kaprio,et al.  Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. , 1999, International journal of epidemiology.

[139]  J. Bousquet,et al.  Perennial rhinitis: An independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey. , 1999, The Journal of allergy and clinical immunology.

[140]  D. Conrad,et al.  Humoral response suppression observed with CD23 transgenics. , 1999, Journal of immunology.

[141]  M. Jessen,et al.  Definition, prevalence and development of nasal obstruction , 1997, Allergy.

[142]  C. Bachert,et al.  IL-5 synthesis is upregulated in human nasal polyp tissue. , 1997, The Journal of allergy and clinical immunology.

[143]  A. Togias,et al.  Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. , 1997, Journal of immunology.

[144]  K. Larsen,et al.  The clinical relationship of nasal polyps to asthma. , 1996, Allergy and asthma proceedings.

[145]  S. Frenkiel,et al.  Local specific IgE production in nasal polyps associated with negative skin tests and serum RAST. , 1985, Annals of allergy.